Skip to main content
. 2014 Jul 1;20(1):41–53. doi: 10.1016/j.cmet.2014.03.031

Figure 4.

Figure 4

Effect of ICV E2 on Energy Balance and the VMH AMPK-SNS-BAT Axis

(A–D) (A) Body weight change (left panel), daily food intake (middle panel), and core temperature (right panel); (B) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel); (C) infrared thermal images (left panel) and quantification of temperature of the skin surrounding interscapular BAT (right panel); and (D) western blot autoradiographic images (left panel) and VMH protein levels of proteins of the AMPK pathway (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol).

(E–H) (E) Body weight change, (F) daily food intake, (G) core temperature, and (H) western blot autoradiographic images of BAT UCP1 protein (left panel) and UCP1 protein levels (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol), previously SC treated with the β3-AR-antagonist SR59230A for 2 days. Error bars represent SEM; n = 7–12 animals per experimental group. ∗ and ∗∗∗p < 0.05 and 0.001 versus vehicle ICV or vehicle ICV vehicle SC; # and ##p < 0.05 and 0.01 versus E2 ICV vehicle SC.